Molecular probes for malignant melanoma imaging

Current Pharmaceutical Biotechnology

Volumn 11, Issue 6, 2010, Pages 590-602

  Ren, Gang ^a   Pan, Ying ^a   Cheng, Zhen ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

MC1R; Melanin; Melanoma; Molecular Imaging; Molecular Probe; PET

Indexed keywords

6D2 RE 188; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; DACARBAZINE; DNA; DOPA; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; HEPTAPEPTIDE; HEXOKINASE; IODINE 123; LEAD 203; MATRIX METALLOPROTEINASE; MELANIN; MELANOCORTIN; MELANOCORTIN RECEPTOR; MELANOMA ANTIGEN; METHIONINE C 11; METRONIDAZOLE; PLATELET DERIVED GROWTH FACTOR; PROOPIOMELANOCORTIN; PROTEINASE; RADIOPHARMACEUTICAL AGENT; SIGMA OPIATE RECEPTOR; SORAFENIB; TECHNETIUM 99M; TEMOZOLOMIDE; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN; DIAGNOSTIC AGENT; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BASEMENT MEMBRANE; BRAIN METASTASIS; CANCER GROWTH; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISULFIDE BOND; DNA SYNTHESIS; GLUCOSE METABOLISM; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; KIDNEY TUBULE ABSORPTION; LIVER; LIVER METASTASIS; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOGENESIS; MELANOMA; METASTASIS; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN METABOLISM; RADIOIMMUNOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; TISSUE SECTION; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; SCINTISCANNING; SKIN TUMOR;

HUMANS; MELANOMA; MOLECULAR IMAGING; MOLECULAR PROBES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650319332     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110792246465     Document Type: Review

References (136)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59. 225-249.
2. Cockburn, M.; Swetter, S.M.; Peng, D.; Keegan, T.H.M.; Deapen, D.; Clarke, C.A. Melanoma underreporting: Why does it happen, how big is the problem, and how do we fix it? J. Am. Acad. Dermatol., 2008, 59. 1081-1085.
3. Olsen, J.H.; Friis, S.; Frederiksen, K. Malignant melanoma and other types of cancer preceding parkinson disease. Epidemiology. 2006, 17. 582-587.
4. Driver, J.A.; Logroscino, G.; Buring, J.E.; Gaziano, J.M.; Kurth, T. A prospective cohort study of cancer incidence following the diagnosis of parkinson's disease. Cancer Epidemiol. Biomarkers Prev. 2007, 16. 1260-1265.
5. Christensen, K.; Doblhammer, G.; Rau, R.; Vaupel, J.W. Ageing populations: The challenges ahead. Lancet. 2009, 374. 1196-1208.
6. Geller, A.C.; Miller, D.R.; Annas, G.D.; Demierre, M.F.; Gilchrest, B.A.; Koh, H.K. Melanoma incidence and mortality among us whites, 1969-1999. JAMA, 2002, 288. 1719-1720.
7. Massoud, T.F.; Gambhir, S.S. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev. 2003, 17. 545-580.
8. Krug, B.; Crott, R.; Lonneux, M.; Baurain, J.; Pirson, A.; Van der Borght, T. Role of pet in the initial staging of cutaneous malignant melanoma: Systematic review. Radiology. 2008, 249. 836-844.
9. Choi, E.A.; Gershenwald, J.E. Imaging studies in patients with melanoma. Surg. Oncol. Clin. N. Am. 2007, 16. 403-430.
10. Veit-Haibach, P.; Vogt, F.M.; Jablonka, R.; Kuehl, H.; Bockisch, A.; Beyer, T.; Dahmen, G.; Rosenbaum, S.; Antoch, G. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur. J. Nucl. Med. Mol. Imaging. 2009, 36. 910-918.
11. Mansour, A. A.3rd.; Kelley, M.C.; Hatmaker, A.R.; Holt, G.E.; Schwartz, H.S. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. Ann. Surg. Oncol. 2010, 17, 1144-1151.
12. 18F-fluoro-3'-deoxy-L-thymidine: A new tracer for staging metastatic melanoma? J. Nucl. Med. 2003, 44. 1927-1932.
13. 18F] FLT PET for diagnosis and staging of thoracic tumours. Eur. J. Nucl. Med. Mol. Imaging. 2003, 30. 1407-1412.
14. Lindholm, P.; Leskinen, S.; Nagren, K.; Lehikoinen, P.; Ruotsalainen, U.; Teras, M.; Joensuu, H. Carbon-11-methionine PET imaging of malignant melanoma. J. Nucl. Med. 1995, 36. 1806-1810.
15. Cook, G.J.; Maisey, M.N.; Fogelman, I. Normal variants, artifacts and interpretative pitfalls in pet imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur. J. Nucl. Med. 1999, 26. 1363-1378.
16. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell. 2000, 100. 57-70.
17. Lacal, P.M.; Failla, C.M.; Pagani, E.; Odorisio, T.; Schietroma, C.; Falcinelli, S.; Zambruno, G.; D'Atri, S. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol. 2000, 115. 1000-1007.
18. Danielsen, T.; Rofstad, E.K. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int. J. Cancer. 1998, 76. 836-841.
19. Westphal, J.R.; Van't Hullenaar, R.; Peek, R.; Willems, R.W.; Crickard, K.; Crickard, U.; Askaa, J.; Clemmensen, I.; Ruiter, D.J.; De Waal, R.M. Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int. J. Cancer. 2000, 86. 768-776.
20. Melnikova, V.O.; Bar-Eli, M. Bioimmunotherapy for melanoma using fully human antibodies targeting mcam/muc18 and IL-8. Pig. Cell Res. 2006, 19. 395-405.
21. Sun, J.; Blaskovich, M.A.; Jain, R.K.; Delarue, F.; Paris, D.; Brem, S.; Wotoczek-Obadia, M.; Lin, Q.; Coppola, D.; Choi, K.; Mullan, M.; Hamilton, A.D.; Sebti, S.M. Blocking angiogenesis and tumorigenesis with gfa-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res. 2004, 64. 3586-3592.
22. Amaravadi, R.K.; Schuchter, L.M.; McDermott, D.F.; Kramer, A.; Giles, L.; Gramlich, K.; Carberry, M.; Troxel, A.B.; Letrero, R.; Nathanson, K.L.; Atkins, M.B.; O'Dwyer, P.J.; Flaherty, K.T. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res. 2009, 15. 7711-7718.
23. Forsberg, F.; Ro, R.J.; Liu, J.B.; Lipcan, K.J.; Potoczek, M.; Nazarian, L.N. Monitoring angiogenesis in human melanoma xenograft model using contrast-enhanced ultrasound imaging. Ultrason Imaging. 2008, 30. 237-246.
24. Leenders, W.; Kusters, B.; Pikkemaat, J.; Wesseling, P.; Ruiter, D.; Heerschap, A.; Barentsz, J.; de Waal, R.M. Vascular endothelial growth factor-a determines detectability of experimental melanoma brain metastasis in gd-dtpa-enhanced mri. Int. J. Cancer. 2003, 105. 437-443.
25. Sivolapenko, G.B.; Skarlos, D.; Pectasides, D.; Stathopoulou, E.; Milonakis, A.; Sirmalis, G.; Stuttle, A.; Courtenay-Luck, N.S.; Konstantinides, K.; Epenetos, A.A. Imaging of metastatic melanoma utilising a technetium-99m labeled RGD-containing synthetic peptide. Eur. J. Nucl. Med. 1998, 25. 1383-1389.
26. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001, 61. 1781-1785.
27. 18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2007, 13. 6610-6616.
28. 18F]galacto-RGD positron emission tomography. Neuro. Oncol. 2009, 11, 861-870.
29. 18F]galacto-RGD. PLoS Med. 2005, 2. e70.
30. 18F]galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer Res. 2006, 12. 3942-3949.
31. Hartmann, P.; Mirtolouei, R.; Untersberger, S.; Ziegler, W.; Hermann, Z.; Richtig, E.; Hofmann-Wellenhof, R.; Grinschgl, S.; Kerl, H.; Smolle, J. Non-invasive imaging of tissue pO2 in malignant melanoma of the skin. Melanoma Res. 2006, 16. 479-486.
32. Vestvik, I.K.; Egeland, T.A.; Gaustad, J.V.; Mathiesen, B.; Rofstad, E.K. Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast-enhanced mri. J. Magn. Reson Imaging. 2007, 26. 1033-1042.
33. 18F]fluoromisonidazole uptake in experimental mouse tumours. Eur. J. Nucl. Med. Mol. Imaging. 2006, 33. 311-318.
34. Mees, G.; Dierckx, R.; Vangestel, C.; Van de Wiele, C. Molecular imaging of hypoxia with radiolabelled agents. Eur. J. Nucl. Med. Mol. Imaging. 2009, 36. 1674-1686.
35. Krohn, K.A.; Link, J.M.; Mason, R.P. Molecular imaging of hypoxia. J. Nucl. Med. 2008, 49 (Suppl 2), 129S-148S.
36. Hofmann, U.B.; Houben, R.; Brocker, E.B.; Becker, J.C. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie. 2005, 87. 307-314.
37. Hofmann, U.B.; Westphal, J.R.; Van Muijen, G.N.; Ruiter, D.J. Matrix metalloproteinases in human melanoma. J. Invest Dermatol. 2000, 115. 337-344.
38. Scherer, R.L.; McIntyre, J.O.; Matrisian, L.M. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev. 2008, 27. 679-690.
39. Sprague, J.E.; Li, W.P.; Liang, K.; Achilefu, S.; Anderson, C. J. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl. Med. Biol. 2006, 33. 227-237.
40. Bem, W.T.; Thomas, G.E.; Mamone, J.Y.; Homan, S.M.; Levy, B.K.; Johnson, F.E.; Coscia, C.J. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991, 51. 6558-6562.
41. Vilner, B.J.; John, C.S.; Bowen, W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55. 408-413.
42. Mach, R.H.; Smith, C.R. al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997, 57. 156-161.
43. Kashiwagi, H.; McDunn, J.E.; Simon, P.O. Jr.; Goedegebuure, P.S.; Xu, J.; Jones, L.; Chang, K.; Johnston, F.; Trinkaus, K.; Hotchkiss, R.S.; Mach, R.H.; Hawkins, W.G. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: Applications in diagnostic imaging and therapy. Mol. Cancer. 2007, 6. 48.
44. 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: Initial studies in mouse tumor models. Nucl. Med. Biol. 1997, 24. 587-593.
45. 125I]n-[2-(4-iodophenyl)ethyl]-n-methyl-2-(1-piperidinyl) ethylamine: A highaffinity ligand for imaging sigma receptor positive tumors. Nucl. Med. Biol. 1996, 23. 761-766.
46. Everaert, H.; Flamen, P.; Franken, P.R.; Verhaeghe, W.; Bossuyt, A. Sigma-receptor imaging by means of i123-IDAB scintigraphy: Clinical application in melanoma and non-small cell lung cancer. Anticancer Res. 1997, 17. 1577-1582.
47. Larisch, R.; Schulte, K.W.; Vosberg, H.; Ruzicka, T.; Muller-Gartner, H.W. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J. Nucl. Med. 1998, 39. 996-1001.
48. 99mTc-annexin v and its biologic evaluation for in vivo imaging of apoptosis after photodynamic therapy. J. Nucl. Med. 2003, 44. 650-656.
49. Mountjoy, K.G.; Robbins, L.S.; Mortrud, M.T.; Cone, R.D. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992, 257. 1248-1251.
50. 84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum. Mol. Genet. 1996, 5. 1663-1666.
51. Healy, E.; Todd, C.; Jackson, I.J.; Birch-Machin, M.; Rees, J.L. Skin type, melanoma, and melanocortin 1 receptor variants. J. Invest Dermatol. 1999, 112. 512-513.
52. Kennedy, C.; ter Huurne, J.; Berkhout, M.; Gruis, N.; Bastiaens, M.; Bergman, W.; Willemze, R.; Bavinck, J.N. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J. Invest Dermatol. 2001, 117. 294-300.
53. Salazar-Onfray, F.; Lopez, M.; Lundqvist, A.; Aguirre, A.; Escobar, A.; Serrano, A.; Korenblit, C.; Petersson, M.; Chhajlani, V.; Larsson, O.; Kiessling, R. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br. J. Cancer. 2002, 87. 414-422.
54. Benjamin, C.L.; Melnikova, V.O.; Ananthaswamy, H.N. Models and mechanisms in malignant melanoma. Mol. Carcinog. 2007, 46. 671-678.
55. Lopez, M.N.; Pereda, C.; Ramirez, M.; Mendoza-Naranjo, A.; Serrano, A.; Ferreira, A.; Poblete, R.; Kalergis, A.M.; Kiessling, R.; Salazar-Onfray, F. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Invest Ophthalmol. Vis. Sci. 2007, 48. 1219-1227.
56. Tatro, J.B.; Wen, Z.; Entwistle, M.L.; Atkins, M.B.; Smith, T.J.; Reichlin, S.; Murphy, J.R. Interaction of an alpha-melanocytestimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res. 1992, 52. 2545-2548.
57. Bohm, M.; Luger, T.A.; Tobin, D.J.; Garcia-Borron, J.C. Melanocortin receptor ligands: New horizons for skin biology and clinical dermatology. J. Invest. Dermatol. 2006, 126. 1966-1975.
58. Holst, B.; Schwartz, T.W. Molecular mechanism of agonism and inverse agonism in the melanocortin receptors: Zn(2+) as a structural and functional probe. Ann. N. Y. Acad. Sci. 2003, 994. 1-11.
59. Hruby, V.J.; Cai, M.; Grieco, P.; Han, G.; Kavarana, M.; Trivedi, D. Exploring the stereostructural requirements of peptide ligands for the melanocortin receptors. Ann. N Y. Acad. Sci. 2003, 994. 12-20.
60. 11), a cyclized peptide analogue of alpha-MSH. J. Med. Chem. 2005, 48. 2985-2992.
61. 18F-labeled alpha-melanocyte-stimulating hormone analog. J. Nucl. Med. 2007, 48. 987-994.
62. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug. Chem. 2007, 18. 765-772.
63. 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl. Med. Biol. 2005, 32. 485-493.
64. 111In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J. Med. Chem. 2002, 45. 3048-3056.
65. 99mtechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000, 60. 5649-5658.
66. Giblin, M.F.; Wang, N.; Hoffman, T.J.; Jurisson, S.S.; Quinn, T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc. Natl. Acad. Sci. USA. 1998, 95. 12814-12818.
67. Froidevaux, S.; Calame-Christe, M.; Tanner, H.; Eberle, A.N. Melanoma targeting with dota-alpha-melanocyte-stimulating hormone analogs: Structural parameters affecting tumor uptake and kidney uptake. J. Nucl. Med. 2005, 46. 887-895.
68. Froidevaux, S.; Calame-Christe, M.; Tanner, H.; Sumanovski, L.; Eberle, A.N. A novel dota-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J. Nucl. Med. 2002, 43. 1699-1706.
69. 111In-DOTA-rhenium cyclized alpha-MSH analog: A novel cyclic-peptide analog with improved tumor-targeting properties. J. Nucl. Med. 2001, 42. 1847-1855.
70. Cheng, Z.; Chen, J.; Quinn, T.P.; Jurisson, S.S. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res. 2004, 64. 1411-1418.
71. Bard, D.R.; Knight, C.G.; Page-Thomas, D.P. A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br. J. Cancer. 1990, 62. 919-922.
72. Bard, D.R. An improved imaging agent for malignant melanoma, based on [nle4, d-phe7]alpha-melanocyte stimulating hormone. Nucl. Med. Commun., 1995, 16. 860-866.
73. Froidevaux, S.; Calame-Christe, M.; Schuhmacher, J.; Tanner, H.; Saffrich, R.; Henze, M.; Eberle, A.N. A gallium-labeled dotaalpha-melanocyte-stimulating hormone analog for pet imaging of melanoma metastases. J. Nucl. Med. 2004, 45. 116-123.
74. 7]-δ-MSH, an δ-melanocyte stimulating hormone analogue. Nucl. Med. Biol., 1997, 24. 171-178.
75. 203Pb-labeled alpha-melanocytestimulating hormone peptide as an imaging probe for melanoma detection. J. Nucl. Med. 2008, 49. 823-829.
76. 177Lulabeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm. 2007, 22. 333-341.
77. 18F-labeled metallopeptides. J. Nucl. Med. 2009, 50. 1865-1872.
78. Wei, L.; Miao, Y.; Gallazzi, F.; Quinn, T.P.; Welch, M.J.; Vavere, A.L.; Lewis, J.S. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl. Med. Biol. 2007, 34. 945-953.
79. 11)CCMSH. Nucl. Med. Biol. 2009, 36. 345-354.
80. 2with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 1995, 38. 3454-3461.
81. Cody, W.L.; Mahoney, M.; Knittel, J.J.; Hruby, V.J.; Castrucci, A.M.; Hadley, M.E. Cyclic melanotropins. 9. 7-d-phenylalanine analogues of the active-site sequence. J. Med. Chem. 1985, 28. 583-588.
82. Shi, Y.; Sharma, S. Metallopeptide approach to the design of biologically active ligands: Design of specific human neutrophil elastase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9. 1469-1474.
83. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int. J. Cancer. 2002, 101. 480-487.
84. 188Re-labeled alpha-melanocytestimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J. Nucl. Med. 2005, 46. 121-129.
85. 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl. Med. Biol. 2006, 33. 723-733.
86. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl. Med. Biol. 1999, 26. 687-693.
87. Garg, P.K.; Alston, K.L.; Welsh, P.C.; Zalutsky, M.R. Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using n-succinimidyl 3-iodobenzoate. Bioconjug. Chem. 1996, 7. 233-239.
88. 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J. Nucl. Med. 2007, 48. 64-72.
89. Yang, J.; Guo, H.; Gallazzi, F.; Berwick, M.; Padilla, R.S.; Miao, Y. Evaluation of a novel Arg-Gly-Asp-conjugated alphamelanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug. Chem. 2009, Epub.
90. Campoli, M.R.; Chang, C.C.; Kageshita, T.; Wang, X.; McCarthy, J.B.; Ferrone, S. Human high molecular weight-melanomaassociated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 2004, 24. 267-296.
91. abagainst a high molecular weight antigen of human melanoma: preliminary experience. Radiology. 1985, 155. 487-492.
92. Kang, N.; Hamilton, S.; Odili, J.; Wilson, G.; Kupsch. J. In vivo targeting of malignant melanoma by 125iodine-and 99mtechnetium-labeled single-chain fv fragments against high molecular weight melanoma-associated antigen. Clin. Cancer Res. 2000, 6. 4921-4931.
93. Siccardi, A.G.; Buraggi, G.L.; Callegaro, L.; Mariani, G.; Natali, P.G.; Abbati, A.; Bestagno, M.; Caputo, V.; Mansi, L.; Masi, R. Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res. 1986, 46. 4817-4822.
94. 2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J. Neurooncol. 2009, 94. 21-30.
95. Jimbow, K.; Miyake, Y.; Homma, K.; Yasuda, K.; Izumi, Y.; Tsutsumi, A.; Ito, S. Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma. Cancer Res. 1984, 44. 1128-1134.
96. Prota, G. The chemistry of melanins and melanogenesis. Fortschr. Chem. Org. Naturst. 1995, 64. 93-148.
97. Prota, G. Melanins, melanogenesis and melanocytes: Looking at their functional significance from the chemist's viewpoint. Pig. Cell Res. 2000, 13. 283-293.
98. Iozumi, K.; Hoganson, G.E.; Pennella, R.; Everett, M.A.; Fuller, B.B. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J. Investig. Dermatol. 1993, 100. 806-811.
99. Pankovich, J.M.; Jimbow, K. Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues. Biochem. J. 1991, 280 (Pt 3). 721-725.
100. Pawelek, J.M. Factors regulating growth and pigmentation of melanoma cells. J. Invest. Dermatol. 1976, 66. 201-209.
101. Velez, A.; Walsh, D.; Karakousis, C.P. Treatment of unknown primary melanoma. Cancer. 1991, 68. 2579-2581.
102. Boni, R.; Steinert, H.; Huch, Boni, R.; Von Schulthess, G.K.; Meyer, J.; Dummer, R.; Burg, G.; Westera, G. Radioiodine-labelled alpha-methyl-tyrosine in malignant melanoma: Cell culture studies and results in patients. Br. J. Dermatol. 1997, 137. 96-100.
103. 15O-water using compartment and noncompartment analysis. J. Nucl. Med. 2001, 42. 248-256.
104. 18FFDOPA PET. Eur. J. Nucl. Med. Mol. Imaging. 2006, 33. 854-855.
105. 2-Net2: a potential small-molecule singlephoton emission computed tomography probe for imaging metastatic melanoma. Cancer Res. 2005, 65. 4979-4986.
106. Labarre, P.; Papon, J.; Moreau, M.F.; Moins, N.; Bayle, M.; Veyre, A.; Madelmont, J.C. Melanin affinity of n-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res. 2002, 12. 115-121.
107. Liu, X.; Pham, T.; Berghofer, P.; Chapman, J.; Greguric, I.; Mitchell, P.; Mattner, F.; Loc'h, C.; Katsifis, A. Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma. Nucl. Med. Biol. 2008, 35. 769-781.
108. Pham, T.Q.; Greguric, I.; Liu, X.; Berghofer, P.; Ballantyne, P.; Chapman, J.; Mattner, F.; Dikic, B.; Jackson, T.; Loc'h, C.; Katsifis, A. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J. Med. Chem. 2007, 50. 3561-3572.
109. Chezal, J.M.; Papon, J.; Labarre, P.; Lartigue, C.; Galmier, M.J.; Decombat, C.; Chavignon, O.; Maublant, J.; Teulade, J.C.; Madelmont, J.C.; Moins, N. Evaluation of radiolabeled (hetero) aromatic analogues of n-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J. Med. Chem. 2008, 51. 3133-3144.
110. Eisenhut, M.; Hull, W.E.; Mohammed, A.; Mier, W.; Lay, D.; Just, W.; Gorgas, K.; Lehmann, W.D.; Haberkorn, U. Radioiodinated n-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: Structure-affinity relationships, metabolic fate, and intracellular localization. J. Med. Chem. 2000, 43. 3913-3922.
111. Dadachova, E.; Casadevall, A. Melanin as a potential target for radionuclide therapy of metastatic melanoma. Future Oncol. 2005, 1. 541-549.
112. Dadachova, E.; Nosanchuk, J.D.; Shi, L.; Schweitzer, A.D.; Frenkel, A.; Nosanchuk, J.S.; Casadevall, A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mab to melanin. Proc. Natl. Acad. Sci. USA. 2004, 101. 14865-14870.
113. Dadachova, E.; Moadel, T.; Schweitzer, A.D.; Bryan, R.A.; Zhang, T.; Mints, L.; Revskaya, E.; Huang, X.; Ortiz, G.; Nosanchuk, J.S.; Nosanchuk, J.D.; Casadevall, A. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother. Radiopharm. 2006, 21. 117-129.
114. Jimbow, K.; Miura, T.; Ito, S.; Ishikawa, K. Phenolic melanin precursors provide a rational approach to the design of antitumor agents for melanoma. Pigment Cell Res. 1989, 2. 34-39.
115. Desbois, N.; Gardette, M.; Papon, J.; Labarre, P.; Maisonial, A.; Auzeloux, P.; Lartigue, C.; Bouchon, B.; Debiton, E.; Blache, Y.; Chavignon, O.; Teulade, J.; Maublant, J.; Madelmont, J.; Moins, N.; Chezal, J. Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma. Bioorg. Med. Chem. 2008, 16. 7671-7690.
116. Plonka, P.M.; Grabacka, M. Melanin synthesis in microorganisms--biotechnological and medical aspects. Acta. Biochim. Pol. 2006, 53. 429-443.
117. Urabe, K.; Aroca, P.; Hearing, V.J. From gene to protein: Determination of melanin synthesis. Pigment Cell Res. 1993, 6. 186-192.
118. 11C labelled tyrosine and dihydroxyphenylalanine. Eur. J. Nucl. Med. 1988, 14. 382-387.
119. Ishiwata, K.; Ido, T.; Takahashi, T.; Iwata, R.; Brady, F.; Hatazawa, J.; Itoh, M. Feasibility study of fluorine-18 labeled dopa for melanoma imaging. Int. J. Rad. Appl. Instrum. B. 1989, 16. 371-374.
120. 125I]IBZM: A potential CNS d-2 dopamine receptor imaging agent. Int. J. Rad. Appl. Instrum. B. 1988, 15. 195-201.
121. Tu, Z.; Xu, J.; Jones, L.A.; Li, S.; Dumstorff, C.; Vangveravong, S.; Chen, D.L.; Wheeler, K.T.; Welch, M.J.; Mach, R.H. Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J. Med. Chem. 2007, 50. 3194-3204.
122. Michelot, J.M.; Moreau, M.F.; Labarre, P.G.; Madelmont, J.C.; Veyre, A.J.; Papon, J.M.; Parry, D.F.; Bonafous, J.F.; Boire, J.Y.; Desplanches, G.G. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J. Nucl. Med. 1991, 32. 1573-1580.
123. Michelot, J.M.; Moreau, M.F.; Veyre, A.J.; Bonafous, J.F.; Bacin, F.J.; Madelmont, J.C.; Bussiere, F.; Souteyrand, P.A.; Mauclaire, L.P.; Chossat, F.M. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-n-(2-diethylaminoethyl 4-iodobenzamide). J Nucl. Med. 1993, 34. 1260-1266.
124. 123I-n-(2-diethylaminoethyl)-2-iodobenzamide: A potential imaging agent for cutaneous melanoma staging. Eur. J. Nucl. Med. Mol. Imaging. 2002, 29. 1478-1484.
125. Maffioli, L.; Mascheroni, L.; Mongioj, V.; Gasparini, M.; Baldini, M.T.; Seregni, E.; Castellani, M.R.; Cascinelli, N; Buraggi, G.L. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(s)-IBZM). J. Nucl. Med. 1994, 35. 1741-1747.
126. 131I labelled potential agent. Int. J. Cancer. 2009, 125. 708-716.
127. 18F-DAFBA: A novel potential pet probe to image melanoma tumors. Bioconjug. Chem. 2009, 20 (3), pp 583-590.
128. Ren, G.; Miao, Z.; Liu, H.; Jiang, L.; Limpa-Amara, N.; Mahmood, A.; Gambhir, S.S.; Cheng, Z. Melanin-targeted preclinical pet imaging of melanoma metastasis. J. Nucl. Med. 2009, 50. 1692-1699.
129. 18F-mel050, a selective probe for melanin with predominantly renal clearance. J. Nucl. Med. 2010, 51, 441-447.
130. 99mTc]oxotechnetium(v) complexes amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma. J. Med. Chem. 2001, 44. 3132-3140.
131. Friebe, M, Mahmood, A.; Spies, H.; Berger, R.; Johannsen, B.; Mohammed, A, Eisenhut, M.; Bolzati, C. Davison, A.; Jones, A.G. '3+1' mixed-ligand oxotechnetium(v) complexes with affinity for melanoma: synthesis and evaluation in vitro and in vivo. J. Med. Chem. 2000, 43. 2745-2752.
132. Syhre, R.; Seifert,. S; Spies, H.; Gupta, A.; Johannsen, B. Stability versus reactivity of "3+1" Mixed-ligand technetium-99m complexes in vitro and in vivo. Eur. J. Nucl. Med. 1998, 25. 793-796.
133. Dadachova, E.; Casadevall, A. Renaissance of targeting molecules for melanoma. Cancer Biother. Radiopharm. 2006, 21. 545-552.
134. Howell, R.C.; Revskaya, E.; Pazo, V.; Nosanchuk, J. D; Casadevall, A.; Dadachova, E. Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Bioconjug. Chem. 2007, 18. 1739-1748.
135. 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol. Ther. 2008, 7. 1116-1127.
136. Revskaya, E.; Jongco, A.M.; Sellers, R.S.; Howell, R.C.; Koba, W.; Guimaraes, A.J.; Nosanchuk, J.D.; Casadevall, A.; Dadachova, E. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin. Cancer Res. 2009, 15. 2373-2379.